A pill to treat postpartum depression? It’s here

The fast-acting pill, paired with psychosocial treatment, offers a comprehensive treatment plan, but price concerns remain

5:00 AM

Author | Patricia DeLacey

woman sitting and using cell pill crib teddy bear blue pink
Justine Ross, Michigan Medicine

Listen to this article on Health Lab's podcast

The first oral medication to treat postpartum depression, zuranolone (branded Zurzuvae), received approval from the Food and Drug Administration in August 2023.

Taken orally once a day for 14 days, the pill starts relieving depressive symptoms after about three days and the effects last up to 45 days.

Zuranolone supplies a mimic of allopregnanolone – a neurohormone that decreases rapidly after pregnancy – that acts on receptors to reverse the withdrawal effects that impact mood.

This mechanism differs from most anti-depressants, which target neurotransmitters and take up to six to eight weeks to take effect.

The fast-acting pill offers more convenience than the postpartum depression infusion treatment, brexanolone (branded Zulresso), which has been available since 2019, but cost concerns remain.

As with all mental health medications, zuranolone should be paired with psychosocial treatment to treat all factors contributing to the disease.

SEE ALSO: A $34,000 Drug for Postpartum Depression Brings Praise, Price Concerns

“We get excited about new medicines – which are wonderful – but we put a lot of resources towards developing medicines when known psychosocial risks need our attention as well. These risks often get forgotten and stay unaddressed,” said Maria Muzik, M.D., M.Sc., a professor in the Michigan Medicine departments of psychiatry and obstetrics and gynecology.

A ‘multifactorial origin’

Like during depressive periods at any other time in life, postpartum depression is characterized by symptoms such as low energy, sad or irritable mood, sleeping/eating too much or too little, or not feeling joy in expected activities, including caring for the baby. In severe cases, postpartum depression can be life-threatening as mothers may experience thoughts of harming themselves or their child.

SEE ALSO: Insomnia and Postpartum Depression: When a New Mom’s Sleep Loss Turns Perilous

Both biological factors, like the shift in the hormonal landscape after birth, and psychosocial factors contribute to the development of postpartum depression, says Muzik.

“Because postpartum depression has a multifactorial origin, we also need multilevel treatments. In clinical practice, we first address psychosocial factors with a wide range of evidence-based psychotherapies and support and then address biological factors with medications,” said Muzik.

Treating postpartum depression

Psychoeducation should come first, says Muzik. Women often don’t realize they are depressed or downplay their symptoms.

“Many women feel guilty for their depressive symptoms, and we must educate them that their symptoms are part of a treatable illness. They are not weak.”

SEE ALSO: A Third of New Moms Had Postpartum Depression During Early Covid

Peer-to-peer support groups, where moms support other moms, are enormously helpful. Psychotherapy, like cognitive behavioral therapy, interpersonal therapy, or parent-infant psychotherapy can help women work through their anxious or depressive feelings and support their parenting confidence while also developing strategies to avert future flare ups.

Until now, the mainstay of biological treatment for postpartum depression were anti-depressants or anti-anxiety medications that increased serotonin levels in the brain called selective serotonin reuptake inhibitors or SSRIs.

The newly approved zuranalone will offer another, mechanistically totally different, option for treating the biological underpinnings of postpartum depression.

“Postpartum depression co-occurs with anxiety even more so than major depressive disorder,” said Muzik.

“Zuranolone works on allopregnanolone receptors to decrease anxiety, insomnia, and depression associated with postpartum depression.”

Side effects of the medication include dizziness and sedation which prohibits patients from driving or operating machinery while taking the medication.

Patients cannot take the medication while pregnant and cannot breastfeed while taking the medication and for a week afterwards.

Importantly, zuranolone has an addictive potential and should be avoided in individuals with a history of addiction.

Cost concerns

It is not yet clear whether zuranolone will remain as costly as its intravenous predecessor, brexanalone.

Currently, zuranolone is FDA approved only for the treatment of postpartum depression and not for major depressive disorder.

Sage Therapeutics, the drug manufacturer, originally projected the price for zuranolone to stay under $10,000 if it was also approved for major depressive disorder. Now that the market is smaller, the price will likely increase.

If it’s not fully subsidized by Medicare or insurance companies, this medication will heighten health care inequities, says Muzik.

Those who can afford the medication or have insurance that covers it will have access and those who do not will not have access.

“I am very excited, but I also wonder what the ramifications are,” continued Muzik.

“My biggest concern is how will those who have the greatest risk and need get access to the medication?"


If you or someone you’re with is having a life-threatening psychiatric emergency, please call 911.

For mental health crises and urgent concerns, dial 988 for the National Suicide and Crisis Lifeline.

More Articles About: Gynecology obstetrics and gynecology Postpartum Depression Adult Psychiatric Treatment Mental Health Mental Health Assessment Women's Health
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of healthcare news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]


Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Featured News & Stories dad on left, mom sitting next to son all talking smiling
Health Lab
How you can teach your kids to stay safe in the sun
A melanoma survivor shares facts and tips about preventing all types of skin cancer.
mushrooms in a microscope
Health Lab
How cannabis and psilocybin might help some of the 50 million Americans experiencing chronic pain
Recent developments represent a dramatic change from long standing federal policy around these substances that has historically criminalized their use and blocked or delayed research efforts into their therapeutic potential.
The Fundamentals Podcast Hero Card Final 1800 x 1350
The Fundamentals
Treating Diabetes & Weight: The Ozempic & Wegovy Effect
Today on The Fundamentals, our guest Dr. Martin Myers, Director of the U-M Elizabeth Weiser Caswell Diabetes Institute, discusses diabetes research in the context of Ozempic, Wegovy, and other drugs that are changing how people think about weight loss. You can learn more about Dr. Myers here, and you can follow the department of molecular and integrative physiology @UMPhysiology on X.
Health Lab
Mother-son heart bond: Woman relives congenital heart journey through newborn
A mother relives congenital heart journey through newborn.
uti written on empty roll of toliet paper on a toliet paper holder with hot pink background
Health Lab
How E. coli get the power to cause urinary tract infections
Research published in PNAS examines how the bacteria Escherichia coli, or E. coli—responsible for most UTIs—is able to use host nutrients to reproduce at an extraordinarily rapid pace during infection despite the near sterile environment of fresh urine.
Michigan Medicine Presents in spotlights on blue background
Michigan Medicine Presents
Michigan Medicine Presents: How to Get into Medical School
Join Dr. Deb Berman, assistant dean for admissions, and Carol Teener, director of admissions, along with two current medical students from the University of Michigan Medical School for answers to your questions about getting into medical school and more. The conversation ranges from GPAs and personal statements to the culture and experiences that make Michigan unique.